As part of our series focussing on medicines available in Australia, we have added a product review of the use of osilodrostat to treat Cushing’s Disease.
This review summarises key pharmacological and clinical data on the use of the adrenal-targeting agent osilodrostat in the treatment of Cushing's Disease of pituitary origin.
It also provides commentary and guidance from Professor Ann McCormack, senior staff specialist in the Department of Endocrinology at St Vincent’s Hospital.
Please login below to download this issue (PDF)